In addition to modifying fundamental pathological processes, non-competitive allosteric inhibitors of CXCR1/2 may have the additional benefit of providing partial relief for pain and, hence, may be a valid therapeutic target for the treatment of RA [41], [42]. This evidence concerns the gene CXCR1 and rheumatoid arthritis.